A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Status: | Completed |
---|---|
Conditions: | Arthritis, Rheumatoid Arthritis |
Therapuetic Areas: | Rheumatology |
Healthy: | No |
Age Range: | Any |
Updated: | 11/18/2012 |
Start Date: | July 2011 |
End Date: | March 2013 |
Contact: | Please reference Study ID Number: ML25641 www.roche.com/about_roche/roche_worldwide.htm |
Email: | genentechclinicaltrials@druginfo.com |
Phone: | 888-662-6728 (U.S. Only) |
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
This multicenter, open-label, single arm study will evaluate the safety of administering
MabThera/Rituxan (rituximab) at a more rapid infusion rate in patients with moderate to
severe rheumatoid arthritis who have had an inadequate response to anti-TNF therapy and are
receiving methotrexate. Patients will receive 2 courses of MabThera/Rituxan separated by 24
weeks, a course consisting of two 1000 mg intravenous infusions of MabThera/Rituxan
separated by 2 weeks. The Day 1 infusion will be administered at the labeled rate (4.25
hours), the Day 15 and Week 24 and 26 infusions over a 2-hour period. The anticipated time
on study treatment is 26 weeks with a 4-week follow-up.
Inclusion Criteria:
- Adult patients, >/= 18 years of age
- Rheumatoid arthritis of >/= 6 months duration, diagnosed according to the revised
1987 American College of Rheumatology criteria
- Inadequate response to at least one approved anti-TNF agent (adalimumab, etanercept,
infliximab, golimumab, or certolizumab)
- Patients who have received 1 to 2 prior courses of rituximab (RTX) may be enrolled,
provided their most recent course of RTX occurred over 6 months but no more than 9
months prior to baseline. The RTX dosage must have been two 1000 mg infusions per
course administered at the standard approved rate
- Methotrexate treatment between 10 and 25 mg/week (oral or parenteral) for at least 8
weeks immediately prior to baseline
Exclusion Criteria:
- Major surgery (including joint surgery) within 8 weeks prior to screening or planned
surgery within 6 months following baseline
- Rheumatic autoimmune disease other than rheumatoid arthritis
- Functional class IV as defined by American College of Rheumatology (ACR) criteria
- Prior history of or current inflammatory joint disease other than rheumatoid
arthritis
- History of severe allergic or anaphylactic reactions to human, humanized or murine
monoclonal antibodies
- Previous serious infusion reaction to any prior biologic therapy
- Known active current or history of recurrent infection
- Evidence of chronic hepatitis B or C infection
- Pregnant or lactating women
- Body weight of > 150 kg
We found this trial at
31
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials